Needham reaffirms Buy on Acadia and Harmony Biosciences
Needham kept Buy ratings on Acadia Pharmaceuticals (target $35) and Harmony Biosciences (target $50), according to TradingView citing Benzinga data.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Needham reiterated its Buy rating on Acadia Pharmaceuticals and kept its price target at $35. The target implies an 83.1% upside from the Oct 16 close of $19.12. The analyst note highlights the approved products NUPLAZID and DAYBUE, along with clinical programs targeting psychosis in Alzheimer's disease and Lewy Body Dementia.
Needham also reiterated its Buy rating on Harmony Biosciences Holdings, with a price target of $50. That represents 31.8% upside from the Oct 16 close of $37.95. Analysts expect WAKIX sales in narcolepsy to exceed expectations, and the orphan drug pipeline, including pitolisant, could widen treatment options.
why it matters
Reiterated ratings from a single broker rarely move markets on their own, since they reflect one firm's view. Biotech investors tend to focus more on clinical trial results and the sales trends the analyst cites.
tags
instruments
sources
- Needham reiterates Buy rating on Acadia Pharmaceuticals, $35 price target — TradingView, 19 October 2026 at 10:07 UTC
- Needham reiterates Buy rating on Harmony Biosciences Hldgs, $50 price target — TradingView, 19 October 2026 at 10:26 UTC
- Needham reiterates Buy rating on Recursion Pharmaceuticals, $8 price target — TradingView, 19 October 2026 at 10:34 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗